Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Completed 3Unknown 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Hepatocellular 66Carcinoma, Renal Cell 38Liver Neoplasms 20Neoplasm Metastasis 17Carcinoma, Non-Small-Cell Lung 16Neoplasms 15Breast Neoplasms 15Melanoma 13Thyroid Neoplasms 10Leukemia, Myeloid, Acute 10Sarcoma 9Lung Neoplasms 8Kidney Neoplasms 8Prostatic Neoplasms 7Ovarian Neoplasms 7Urinary Bladder Neoplasms 6Pancreatic Neoplasms 6Glioblastoma 6Brain Neoplasms 6Colorectal Neoplasms 5Carcinoma, Medullary 5Thyroid Carcinoma, Anaplastic 4Stomach Neoplasms 4Rectal Neoplasms 4Gliosarcoma 4Gallbladder Neoplasms 4Colonic Neoplasms 4Breast Neoplasms, Male 4Thyroid Diseases 3Thyroid Cancer, Papillary 3

Interventions

Gemcitabine 26Capecitabine 16Oxaliplatin 14Fluorouracil 13Cisplatin 12Leucovorin 9pembrolizumab 5Erlotinib Hydrochloride 5Bevacizumab 5durvalumab 4Trastuzumab 4Specimen Handling 4Sorafenib 4Magnetic Resonance Spectroscopy 4130-nm albumin-bound paclitaxel 4trifluridine tipiracil drug combination 3Lapatinib 3Irinotecan 3Carboplatin 3Biopsy 3tremelimumab 2toripalimab 2regorafenib 2lenvatinib 2dehydroftorafur 2cobimetinib 2atezolizumab 2anlotinib 2Nivolumab 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Gallbladder Neoplasms × Sorafenib × Clear all
NCT02836847 2018-05-07

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Shanghai Jiao Tong University School of Medicine

Phase 2 Unknown
152 enrolled
Gastrointestinal

Gallbladder Neoplasms

NCT00919061 2016-02-03

Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
39 enrolled 7 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms

NCT01093222 2015-06-30

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled 16 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Klatskin Tumor

NCT00238212 2013-01-14

S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡